{"mainPropery":{"diseaseId":7409,"diseaseName":"Pneumocystis jirovecii pneumonia","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/7409/pneumocystis-jirovecii-pneumonia","synonyms":["Pneumocystis pneumonia","Pneumocystis carinii pneumonia (former)"],"synonyms-with-source":[{"name":"Pneumocystis pneumonia","source":"CDC"},{"name":"Pneumocystis carinii pneumonia (former)","source":"CDC"}],"identifiers":[]},"diseaseCategories":[],"organizations":[],"resource descriptions":[],"overviewQuestion":{"questionId":0,"dateModified":"0001-01-01T00:00:00"},"basicQuestions":[],"references":[],"relatedDiseases":[],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[{"productId":223,"genericName":"Atovaquone","tradeName":"Mepron®","tradeLink":"http://us.gsk.com/products/assets/us_mepron.pdf","manufacturer":"","sponsor":"Glaxo Wellcome Inc.","indication":"For the acute oral treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in patients who are intolerant to trimethoprim-sulfamethoxazole. Prevention of PCP in patients who are intolerant to trimethoprim-sulfamethoxazole.","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Mepron","medlinePlusLink":""},{"productId":185,"genericName":"Pentamidine isethionate","tradeName":"Nebupent®","tradeLink":"http://www.apppharma.com/ProductDetail.aspx?Id=85","manufacturer":"APP Pharmaceuticals","sponsor":"Fujisawa USA, Inc.","indication":"Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Nebupent","medlinePlusLink":"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a685029.html"},{"productId":330,"genericName":"Trimetrexate glucuronate","tradeName":"Neutrexin®","tradeLink":"http://www.medimmune.com/products/bookmarks/neutrexin_pi.html","manufacturer":"","sponsor":"Medimmune Oncology, Inc.","indication":"Concurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe PCP in immunocompromised patients who are intolerant of, or are refractory to, trimethoprim sulfamethoxazole.","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Neutrexin","medlinePlusLink":"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a694019.html"},{"productId":184,"genericName":"Pentamidine isethionate","tradeName":"Pentam 300®","tradeLink":"http://www.apppharma.com/ProductDetail.aspx?Id=91&name=Pentam%3csup%3e®%3c/sup%3e%20300%20(sterile%20pentamidine%20isethionate)","manufacturer":"APP Pharmaceuticals","sponsor":"Fujisawa USA, Inc.","indication":"Treatment of Pneumocystis carinii pneumonia.","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Pentam+300","medlinePlusLink":"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a685029.html"}],"EncodedName":"Pneumocystis_jirovecii_pneumonia"}